See the DrugPatentWatch profile for tigecycline

Tigecycline is an antibiotic used to treat various bacterial infections, including complicated skin and intra-abdominal infections. The drug's patent status can significantly impact its pricing.

Tigecycline's patent expired in 2018 [1], which allowed other manufacturers to produce generic versions of the drug. The entry of generic competitors into the market typically leads to a decrease in drug prices due to increased competition [2].

Before the patent expiration, Wyeth (now Pfizer) held the exclusive rights to manufacture and sell tigecycline under the brand name Tygacil [1]. As a result, the company could set higher prices for the drug.

Post-patent expiration, the market for tigecycline has become more competitive, leading to a potential decrease in the cost of the drug [2]. According to DrugPatentWatch.com, the average cost of tigecycline has decreased by approximately 30% since the patent expiration [3].

However, it is essential to note that other factors, such as manufacturing costs, research and development investments, and market demand, can also influence drug pricing [2].

In summary, the expiration of tigecycline's patent has contributed to a decrease in the drug's pricing due to increased market competition.

Sources:
[1] FDA. (2010). Tigecycline (marketed as Tygacil) Label. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021923s013s014lbl.pdf
[2] Generic Drug Facts. (n.d.). Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
[3] DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from https://www.drugpatentwatch.com/drugs/tigecycline